Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

4D Molecular Therapeutics, Inc. FDMT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$25.33
+162.2%

4D Molecular Therapeutics, Inc. (FDMT) is a Biotechnology company in the Healthcare sector, currently trading at $9.66. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is FDMT = $25 (+162.2% upside).

Valuation: FDMT trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25).

Financials: revenue is $85M, +76885.7%/yr average growth. Net income is $140M (loss), growing at -15.5%/yr. Net profit margin is -164.4% (negative). Gross margin is 91.1% (+115.1 pp trend).

Balance sheet: total debt is $21M against $506M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 9.39 (strong liquidity). Debt-to-assets is 3.8%. Total assets: $567M.

Analyst outlook: 10 / 14 analysts rate FDMT as buy (71%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).

$25.33
▲ 162.22% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for 4D Molecular Therapeutics, Inc., the average price target is $25.33, with a high forecast of $33.00, and a low forecast of $17.00.
Highest Price Target
$33.00
Average Price Target
$25.33
Lowest Price Target
$17.00

FDMT SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FDMT

✓
VALUE Pass
100/100
FDMT trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25). Forward PEG -5.27 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $25, implying +158.8% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
FDMT: +76885.7%/yr revenue is, -15.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet FDMT: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 9.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
FDMT: Gross margin is 91.1% (+115.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 10 / 14 analysts rate FDMT as buy (71%). Analyst consensus target is $25 (+158.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
FDMT: Net profit margin is -164.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.235-12.34
Volume1.05M
Avg Volume (30D)761.58K
Market Cap$493.16M
Beta (1Y)2.93
Share Statistics
EPS (TTM)-2.42
Shares Outstanding$57.93M
IPO Date2020-12-11
Employees227
CEODavid H. Kirn
Financial Highlights & Ratios
Revenue (TTM)$85.21M
Gross Profit$77.58M
EBITDA$-151.92M
Net Income$-140.11M
Operating Income$-159.55M
Total Cash$402.66M
Total Debt$21.41M
Net Debt$-38.83M
Total Assets$566.71M
Price / Earnings (P/E)-4
Price / Sales (P/S)5.79
Analyst Forecast
1Y Price Target$26.00
Target High$33.00
Target Low$17.00
Upside+169.2%
Rating ConsensusBuy
Analysts Covering14
Buy 71% Hold 21% Sell 7%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS35104E1001

Price Chart

Track all markets on TradingView
FDMT
4D Molecular Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.24 52WK RANGE 12.34

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 NVCT
NVCT
Nuvectis Pharma, Inc.
$8.73
+3.19%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message